Tue, Sep 16, 2014, 3:37 AM EDT - U.S. Markets open in 5 hrs 53 mins


% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

daweasl652 51 posts  |  Last Activity: Sep 5, 2014 12:19 PM Member since: Apr 21, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by saulirosenberg Sep 5, 2014 11:40 AM
    daweasl652 daweasl652 Sep 5, 2014 12:19 PM Flag


    before year end, Oncs will announce a Ph 2b trial, I think the plan is to combine an anti PD-1 inhibitor with EP/IL-12. - The announcement of first patient enrolled will increase share price.

  • daweasl652 daweasl652 Sep 5, 2014 12:14 PM Flag

    ONCS - 11:34:57
    Bought 5000s @ $0.575 ..... - hopefully $1+ a share by year end. glta.
    - the (persistent) weasl. ..missed 5k @.531 last week, mm's gave it to big money @ .5311

  • daweasl652 daweasl652 Sep 4, 2014 10:04 AM Flag

    neither : )

  • With an upside of 30% in 5 days, do you guys see a retrace within the next couple trading days ? Tia.

  • Reply to

    Best Fall Catalyst Play

    by jbem777 Sep 3, 2014 10:30 AM
    daweasl652 daweasl652 Sep 3, 2014 1:24 PM Flag

    on rare occasion sal, you do make sense...and this is one of them - LOL ...I am hoping for a small pullback...wanted to buy at .44-.46 .....The 40's might be gone, ..c'est la vie {?} GL

  • Reply to

    .536 at 9:45am

    by daweasl652 Sep 3, 2014 9:48 AM
    daweasl652 daweasl652 Sep 3, 2014 9:56 AM Flag

    .5499 .......ridiculous, ,,,,,I wanted to buy at .42 last thrusday or fri..... can you say ..........

    . . . .. the cat is out of the bag . .. . glta.

  • daweasl652 by daweasl652 Sep 3, 2014 9:48 AM Flag

    ....another 15%+ today ?

  • daweasl652 daweasl652 Sep 2, 2014 11:12 AM Flag

    I guess i'm the only one freaked out angry ..#%## ! -- .42 last thurs....planned on buying more today....got some at .48....I hate the internet and the MM's too.! Show me .48 again, dam . . it - rant over.

  • my order for 2500 shares went unfilled on Fri. ..placed order at 2:45pm - $ .431
    10,000 shares go off at 3:45pm - $.4311 , when I saw that I knew they were going to #$#& me. -
    __15% upside in past 5 days, hoping for a pullback this week, I feel like that might not happen.

  • Reply to

    go to I hub and read

    by oilup12345 Aug 18, 2014 8:52 PM
    daweasl652 daweasl652 Aug 18, 2014 11:19 PM Flag

    I am - 10k sh. beginning tomorrow, - small buys , 2500, 1k, etc, filled by thur or fri.

    ....." milestones [2014] .......of unprecedented significance . .. .. . .. "

  • Intratumoral injections of plasmid DNA encoding interleukin-12 (IL-12), facilitated in its delivery by electroporation, results in tumor regression in patients with both metastatic melanoma and Merkel cell carcinoma, according to findings reported at the 2013 World Cutaneous Malignancies Congress on Sunday, July 27, in San Diego.

    “IL-12 is a very powerful immune-stimulating protein. There was excitement for IL-12 in the 1980s and 1990s, but systemic toxicity prevented further development of it. Since that time, investigators have been trying to deliver IL-12 in creative ways, and this is one example of such an approach,” said Shailender Bhatia, MD, of the Seattle Cancer Care Alliance in Seattle.

    Electroporation can transduce, with high efficiency, plasmid DNA directly into melanoma and Merkel cell carcinoma cells. The IL-2 expression remains concentrated within the tumor microenvironment, with no systemic spillage. This stimulates innate and adaptive immune responses while avoiding toxicities associated with systemic IL-12 therapy, he explained to The ASCO Post.

    - Electroporation can transduce, with high efficiency, plasmid DNA directly into . . . carcinoma cells.

    - The IL-12 expression remains concentrated within the tumor microenvironment . . . .

    - This [EP/IL-12] stimulates innate and adaptive immune responses while avoiding toxicities . . . .

  • 1st Q ending 3/31/14 - 48% .... 14 New Positions

    2nd Q ending 6/30/14 - 56% .... 52 Institutional Holders. Total shares held, 10M. .... s/o 18M

  • daweasl652 daweasl652 Aug 7, 2014 11:30 PM Flag

    nice find ............Oncs working up final data from asco abstract ....? the ph II trial.

  • written by David Jackson 8/6/14 .............a small section
    Personally, I take Seeking Alpha articles by authors with positions in the stocks they write about far more seriously than articles by authors without positions in the stocks they write about. They have more on the line; they care more; they've probably dug deeper.

    So, is it wrong to take a position in a stock and then write about it on Seeking Alpha? Absolutely not. Just because someone has a financial interest in the stock they are writing about doesn't mean they are a front runner, and doesn't mean they are a manipulator. In fact, articles about stocks by real investors are more rigorous and have greater credibility.

    If you're an investor with valuable insight into stocks, we and our readers want to hear what you have to say. Give us your real name, sign our compliance agreement, and start submitting articles to our editors

    also ..." Emerging hedgefund managers have told us they attract more LP's on Seeking Alpha than any other platform" ._____ LP's ?? Long plays ? ...a guess.

    - "articles about stocks by real investors are more rigorous and have greater credibility." Think FB87.

    Imho - up 15% yesterday, up 15% today. The Article. Millions read it, retail and hedgefunds. Fact.

  • daweasl652 daweasl652 Aug 6, 2014 11:01 PM Flag

    One of the primary mechanisms of antitumor action is through antibody-dependent cell-mediated cytotoxicity whereby a natural killer (NK) cell binds to the antibody-targeted tumor cell and mediates the killing function Therefore, therapies that augment NK cell function may uniquely offer the ability to improve the activity of monoclonal antibodies without increasing toxicity to non-cancer cells.

    Dr. Kohrt sought to enhance trastuzumab's antitumor activity by increasing its ability to recruit the immune system to attack cancer cells. To do this, Dr. Kohrt tested the activity of fully competent NK cells. Following injection of trastuzumab, the NK cells that encountered trastuzumab-coated, HER2-expressing cells became activated and expressed the costimulatory receptor, CD137. When an agonist antibody targeting CD137 was added subsequent to trastuzumab injection a 50% increase in the cytotoxic activity of the NK cells was found. When the treatment regimen was repeated weekly for three weeks, the combination treatment resulted in prolonged control of tumor growth and a significant improvement in survival in a xenotransplant mouse model. Dr. Kohrt and colleagues further found that the success of this targeted antibody therapy, augmented with CD137, was not limited to HER2-positive breast cancers. They showed that the antitumor toxicity induced by rituximab, an antibody targeted to the immune system B cell protein, was also amplified by subsequent CD137 administration in an animal model of lymphoma.

    Overall, the results of these studies demonstrated that sequential targeting of the CD137 receptor successfully stimulates the immune response and enhances antibody-dependent cell-mediated cytotoxicity. This novel strategy targeting both the tumor and the immune system may thus offer new opportunities to enhance the efficacy of therapeutic antibodies in breast cancer. Clinical investigations are now warranted to determine if this hypothesis holds true in patients.

  • Reply to

    Furbush great write up in SA

    by sxsess Aug 6, 2014 11:52 AM
    daweasl652 daweasl652 Aug 6, 2014 12:26 PM Flag


    An excellent write up- well balanced, The N.Y.Times needs you.(ha) - Your article is the reason we could be up as much as 15% in one day ! GL

  • daweasl652 daweasl652 Aug 5, 2014 4:17 PM Flag

    98% of gaps get filled (my #'s) .....it may take one year , but i'm a believer - The gap always fills -

    .34 to .35 is not a gap, .....a close of .34 and an open of .37 and up from there would be considered a gap'

    gonna take me awhile, will look at historical prices for past year....every penny needs to be traded at some point to have no gap. .......

  • All that money and they can't hire programmers ? when I reply to a post with useless drivel . .. .

    rant over : )

  • Reply to

    Upcoming Catalysts

    by baseball_b_rod Jul 29, 2014 11:02 AM
    daweasl652 daweasl652 Jul 30, 2014 6:22 PM Flag

    Forty five cents a share. - Unfortunately, the valuation is real and correct. A true reflection of what Oncs shares are worth today.

  • Reply to

    ascopost article - 7/29/14

    by daweasl652 Jul 28, 2014 5:06 PM
    daweasl652 daweasl652 Jul 28, 2014 5:33 PM Flag

    Should be 7/29/13 ----- yahoo deleted my first 2 attempts cause I tried to include the link,,, then I cussed yahoo out and they deleted that too ......

0.5101-0.0074(-1.43%)Sep 15 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT
Tesla Motors, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT